Host–Guest Interaction Study of Olmesartan Medoxomil with β-Cyclodextrin Derivatives

Olmesartan medoxomil (OLM) is a selective angiotensin II receptor antagonist used in the treatment of hypertension. Its therapeutic potential is limited by its poor water solubility, leading to poor bioavailability. Encapsulation of the drug substance by two methylated cyclodextrins, namely randomly...

Full description

Bibliographic Details
Published in:	Molecules
Main Authors:	Minodora Andor, Claudia Temereancă, Laura Sbârcea, Adriana Ledeți, Dana Emilia Man, Cristian Mornoș, Amalia Ridichie, Denisa Cîrcioban, Gabriela Vlase, Paul Barvinschi, Angela Caunii, Renata-Maria Văruţ, Cristina Maria Trandafirescu, Valentina Buda, Ionuț Ledeți, Matilda Rădulescu
Format:	Article
Language:	English
Published:	MDPI AG 2024-05-01
Subjects:	olmesartan medoxomil cyclodextrins inclusion complex molecular encapsulation solubility enhancement spectroscopic methods
Online Access:	https://www.mdpi.com/1420-3049/29/10/2209

Similar Items

Host–Guest Complexation of Olmesartan Medoxomil by Heptakis(2,6-di-O-methyl)-β-cyclodextrin: Compatibility Study with Excipients
by: Dana Emilia Man, et al.
Published: (2024-12-01)

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

Olmesartan medoxomil-loaded mixed micelles: Preparation, characterization and in-vitro evaluation
by: Mohamed A. El-Gendy, et al.
Published: (2017-12-01)

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
by: Mac Arturo Murillo-Fernández, et al.
Published: (2022-02-01)

Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation
by: Rania Moataz El-Dahmy, et al.
Published: (2023-03-01)

Cleaning validation for residual estimation of olmesartan medoxomil on stainless steel surface of pharmaceutical manufacturing equipments using swab sampling and HPLC-DAD method
by: Nitin Dubey, et al.
Published: (2013-06-01)

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)
by: Park JS, et al.
Published: (2016-08-01)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: R. P. Mason
Published: (2012-06-01)

Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
by: Iwona Dams, et al.
Published: (2015-12-01)

Development and validation of stability-indicating RP-HPLC method for determination of Olmesartan medoxomile in pharmaceutical dosage form and identification, characterization of alkaline degradation impurity of Olmesartan medoxomile drug substance as well as drug product
by: Jain P.S., et al.
Published: (2012-01-01)

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS
by: J. M. Neutel, et al.
Published: (2011-04-01)

Efficacy and safety of olmesartan medoxomil‐amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single‐arm, multi‐center, real‐world study
by: Zhaoqiang Cui, et al.
Published: (2024-01-01)

Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines
by: Omboni S, et al.
Published: (2015-10-01)

High throughput microwell spectrophotometric assay for olmesartan medoxomil in tablets based on its charge-transfer reaction with DDQ
by: Darwish Ibrahim A., et al.
Published: (2014-03-01)

EFFECTS OF OLMESARTAN ON LOCAL AND REGIONAL RIGIDITY OF ARTERIES IN ISCHEMIC HEART DISEASE
by: I. B. Matrosova, et al.
Published: (2014-06-01)

Simultaneous quantitative analysis of olmesartan, amlodipine and hydrochlorothiazide in their combined dosage form utilizing classical and alternating least squares based chemometric methods
by: Darwish Hany W., et al.
Published: (2016-03-01)

Enhancing Oral Absorption of an Ester Prodrug by Coating Drug Crystals with Binary Lipid Systems and Evaluating the Influence of Compositions
by: Xiaowei Dong, et al.
Published: (2025-09-01)

Encapsulation of Risperidone by Methylated β-Cyclodextrins: Physicochemical and Molecular Modeling Studies
by: Laura Sbârcea, et al.
Published: (2020-12-01)

Looking for an optimal antihypertensive combination. Focus on azilsartan medoxomil/chlorthalidone
by: M. D. Smirnova, et al.
Published: (2025-01-01)

Enteropathy Associated with Olmesartan
by: Bruno Moreira da Silva, et al.
Published: (2016-03-01)

MODERN OPPORTUNITIES FOR ANTIHYPERTENSION THERAPY: THE PLACE OF AZILSARTAN MEDOXOMIL
by: V. V. Skibitsky, et al.
Published: (2017-12-01)

Olmesartan-Associated Enteropathy: An Unexpected Cause of Chronic Diarrhoea
by: Mónica Martins Teixeira, et al.
Published: (2019-04-01)

Development and Evaluation of a Modified Fixed-Dose Combination Antihypertensive Tablet Containing S-Amlodipine Besylate: A Bioequivalence and Stability Study
by: Hyeon Woo Moon, et al.
Published: (2025-09-01)

ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: THE ESPORT STUDY
by: E. Malacco, et al.
Published: (2012-02-01)

Risperidone/Randomly Methylated β-Cyclodextrin Inclusion Complex—Compatibility Study with Pharmaceutical Excipients
by: Laura Sbârcea, et al.
Published: (2021-03-01)

Host–Guest Complexation of Itraconazole with Cyclodextrins for Bioavailability Enhancement
by: Lenuţa-Maria Şuta, et al.
Published: (2024-04-01)

Oxidative Thermolysis of Sulfobutyl-Ether-Beta-Cyclodextrin Sodium Salt: A Kinetic Study
by: Ionuț Ledeți, et al.
Published: (2025-01-01)

Olmesartan-associated Enteropathy with Acute Kidney Injury
by: Moo Jin Kang, et al.
Published: (2022-03-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
by: V. V. Fomin
Published: (2013-08-01)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
by: Attila Juhasz, et al.
Published: (2018-02-01)

Up-to-Date Aspects of Antihypertensive Therapy from the Viewpoint of Cardioand Nephroprotective Action: Olmesartan
by: A. G. Evdokimova, et al.
Published: (2020-05-01)

Atypical Rapid Onset of Olmesartan-Induced Enteropathy with Recurrence After Rechallenging
by: Lila Bekkai, et al.
Published: (2025-07-01)

CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION
by: A G Evdokimova, et al.
Published: (2016-03-01)

Olmesartan worsening known thrombocytopenia. A rare side effect of antihypertensive drugs
by: Elias A. Sanidas, et al.
Published: (2017-01-01)

Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis
by: Ling Zhu, et al.
Published: (2024-07-01)

Clinical and Magnifying Narrow-Band Imaging Endoscopic Finding–Olmesartan-Associated Collagenous Gastroduodenitis
by: Pankaj Desai, et al.
Published: (2020-06-01)

Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation
by: Ali Nasr, et al.
Published: (2016-06-01)

Investigation of hydrolysis of olmesartan medoxomil in different pH buffers by simultaneously measuring olmesartan medoxomil and olmesartan.
by: Lauren Landry, et al.
Published: (2025-01-01)

Severe Hepatitis Complicating Olmesartan Enteropathy: A Case Report
by: Ruyi Tan, et al.
Published: (2024-04-01)